You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Both RT-PCR tests are for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B from throat swab samples.
The firm's assay is also CE marked for use with nasal swabs, nasopharyngeal swabs, nasal wash and aspirates, and bronchoalveolar lavages.
The test can be used directly on any open instrument, including portable systems, and it allows for detection of pathogens in about 75 minutes.
Overall, GenMark's ePlex Respiratory Pathogen Panel 2 provides results for more than 20 viruses and bacteria, including SARS-CoV-2, flu A and B, RSV, and rhinovirus.
The companies are positioning the test, called SeptiCyte Rapid, for use in triaging COVID-19 patients who could be at greater risk for progressing to sepsis.
The PCR-based panel is designed to differentiate between SARS-CoV-2 and other common winter infections with high specificity and sensitivity.
The Signatera test is optimized for molecular residual disease (MRD) assessment and for monitoring treatment in cancer patients.
Zymo Research said that the Quick SARS-CoV-2 rRT-PCR kit includes ready-to-use reaction mixtures that reduce hands-on time and eliminate human errors during the set-up process.
The firm had been distributing BGI's SARS-CoV-2 test kit but will stop distributing it effective immediately, OpGen's CEO said.
The firm said its genetic tests for breast, prostate, and colorectal cancers and melanoma assess a patient's personal cancer risks and guide personalized prevention.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.